Last updated: 2026-09-05 17:16:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Lyell Immunopharma, Inc. (LYEL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $14.37, with a market capitalization of $366.47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11.21 to $45.00. This page covers its latest market performance, valuation, price trends and company information.
$366.47M | |
$14.29 | |
$396.80 | |
$7.65 | |
$14.32 | |
45.69K | |
-- | |
-- | |
$45.00 | |
$11.21 | |
-- | |
-- |
Lyell Immunopharma, Inc. (LYEL) last closed at $14.32 as of 2026-09-04 23:31:00, unchanged from the previous close of $14.32.
During the latest regular trading session, LYEL traded between $7.65 and $396.80, with a volume of 45.69K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Lyell Immunopharma, Inc. (LYEL) moved from $14.51 to $14.37, representing a decline of 0.94% ($0.14).
The stock traded between $14.06 and $14.75 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 69.47 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 9.4%
LYEL is currently trading at $14.37, placing it 9.4% of the way from its 52-week low of $11.21 to its 52-week high of $45.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 161 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lyell Immunopharma, Inc. (LYEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.